UPDATE: Goldman Sachs Upgrades Myriad Genetics to Buy on Expanded Portfolio, Domestic Bias

Goldman Sachs raises its rating on Myriad Genetics

and raises its price target from $27 to $29. Goldman Sachs says, "We upgrade shares of MYGN to Buy from Neutral for four reasons: (1) we believe the recent reimbursement concerns are overdone and believe that the patent debate does not pose near/medium term risk; (2) MYGN's highly US-focused business offers several new product catalysts; (3) we see potential for improved capital allocation to drive share outperformance in 2H; and (4) we believe the scarcity value of established Diagnostics assets warrants an M&A premium in our price target methodology." MYGN closed at $23.77 on Friday.